This trial is active, not recruiting.

Conditions aortic valve stenosis, aortic valve stenosis with insufficiency, regurgitation, aortic valve, aortic valve incompetence
Treatment edwards intuity valve
Sponsor Edwards Lifesciences
Start date September 2012
End date August 2016
Trial size 950 participants
Trial identifier NCT01700439, 2011-02


The purpose of the clinical study is to prove that the heart valve device is safe, effective, and performs as intended.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
All subjects enrolled into the study are implanted with the EDWARDS INTUITY Valve System.
edwards intuity valve
Surgical replacement of the aortic valve with the EDWARDS INTUITY valve.

Primary Outcomes

Long term Performance: Clinically acceptable function by echocardiogram
time frame: All subjects will be assessed for clinical follow-up at the following intervals: Discharge, 1 mo., 3 mo., 1 yr and annually thereafter thru 5 yr follow-up per subject.

Secondary Outcomes

Hemodynamic performance assessed by echocardiogram
time frame: All subjects will be assessed for clinical follow-up at the following intervals: Discharge, 1 mo., 3 mo., 1 yr and annually thereafter thru 5 yr follow-up per subject.

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Inclusion Criteria - Subjects will be required to meet all inclusion criteria: 1. Male or female, age 18 years or older 2. Has aortic stenosis or stenosis-insufficiency of an aortic valve requiring a planned replace-ment as indicated in the preoperative evaluation 3. Is scheduled to undergo planned aortic valve replacement with or without concomitant coronary bypass surgery 4. Provide written informed consent 5. Geographically stable and agrees to attend follow-up assessments until all subjects have completed 5 years of follow up Exclusion Criteria: - Exclusion Criteria - Subjects will not be eligible for trial participation if any of the following criteria are present: 1. Pure aortic insufficiency 2. Requires emergency surgery 3. Previous aortic valve replacement 4. Had prior mitral, tricuspid or pulmonic valve surgery, which included implant of a bioprosthetic valve, mechanical valve, or annuloplasty ring that will remain in situ 5. Requires multiple valve replacement/repair 6. Requires a surgical procedure outside of the cardiac area (e.g., vascular endarterectomy, vascular bypass, tumor removal) 7. Aneurysm of the aortic root and/or ascending aorta requiring surgical intervention 8. Active endocarditis/myocarditis or endocarditis/ myocarditis within 3 months prior to the scheduled AVR surgery 9. Myocardial infarction (MI) within thirty (30) days prior to valve replacement surgery 10. Renal insufficiency as determined by creatinine ≥ 2.5 mg/dL at screening or end-stage renal disease requiring chronic dialysis 11. Hyperparathyroidism 12. MRI or CT-scan confirmed cerebrovascular accident (CVA), or transient ischemic attack (TIA) within 6 months (180 days) of the procedure 13. Presence of non-cardiac disease limiting life expectancy to less than 12 months 14. Hypertrophic obstructive cardiomyopathy (HOCM) 15. Left ventricular ejection fraction ≤ 25% 16. Documented history of substance (drug or alcohol) abuse within the last 5 years 17. Echocardiographic evidence of an intra-cardiac mass, thrombus, or vegetation 18. Hemodynamic or respiratory instability requiring inotropic support, mechanical circulatory support, or mechanical ventilation within 30 days prior to the procedure 19. Pregnancy, lactation, or planning to become pregnant; 20. Currently incarcerated or unable to give voluntary informed consent 21. Leucopenia (WBC < 3.5x 103/µL), or acute anemia (Hgb < 10.0 gm/dL or 6 mmol/L), or thrombocytopenia (platelet count < 50x 103/µL), or history of bleeding diathesis or coagulopathy 22. History of myxomatous disease/connective tissue disorders (e.g., Marfan's Syndrome) 23. Current or recent participation (within 6 weeks prior to surgery) in an investigational drug or device trial _____ Intra-operative Exclusion Criteria 24. Anatomic variances which contraindicate implant of the trial valve, such as: 1. anomalous coronary arteries 2. annular deformation or extensive calcification of the annulus or aortic root which cannot be removed 3. significant calcium on the anterior mitral leaflet 4. pronounced septal calcification 5. position of coronary ostia relative to Model 8300ACD valve that would result in obstruction of blood flow 25. Available devices are not suitably sized for the subject's annulus

Additional Information

Official title Multi-CenTer Experience With the Rapid Deployment EDWARDS INTUITY Valve System FOR Aortic Valve ReplaceMent
Principal investigator Glenn Barnhart, MD
Description This is a prospective, non-randomized, multi-center trial. Up to 950 subjects will be enrolled at up to 35 centers in the US. After re-placement of their aortic heart valve with the EDWARDS INTUITY valve system, each patient will have routine follow-up tests at the following intervals: discharge, 3 months, 1 year, and annually the-reafter for a minimum of five years.
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Edwards Lifesciences.